SEC Company Response from ADMA BIOLOGICS, INC. (ADMA) (CIK 0001368514) (ADMA) — Apr 30, 2013
ADMA BIOLOGICS, INC. (ADMA) (CIK 0001368514)
Date: April 30, 2013 · CIK: 0001368514 · Accession: 0001193805-13-000858
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-186579
Letter
Re:
Unassociated Document
[ADMA Biologics Letterhead]
April 30, 2013
United States Securities and Exchange Commission
100 F Street, N.E.
Washington, D.C. 20549
ADMA Biologics, Inc. (the “Company”)
Registration Statement on Form S-1, as amended
File No. 333-186579
Ladies and Gentlemen:
Pursuant to Rule 461 of Regulation C promulgated under the Securities Act of 1933, as amended, the Company hereby requests that the effectiveness of the above-captioned Registration Statement be accelerated to 4:00 p.m. Eastern Time on April 30, 2013, or as soon thereafter as is practicable.
In connection with this letter, the Company acknowledges that:
· should the Securities and Exchange Commission (the “Commission”) or the staff, acting pursuant to delegated authority, declare the filing effective, it does not foreclose the Commission from taking any action with respect to the filing;
· the action of the Commission or the staff, acting pursuant to delegated authority, in declaring the filing effective, does not relieve the Company from its full responsibility for the adequacy and accuracy of the disclosure in the filing; and
· the Company may not assert staff comments and the declaration of effectiveness as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States.
Very truly yours,
ADMA BIOLOGICS, INC.
Show Raw Text
CORRESP
1
filename1.htm
Unassociated Document
[ADMA Biologics Letterhead]
April 30, 2013
United States Securities and Exchange Commission
100 F Street, N.E.
Washington, D.C. 20549
Re:
ADMA Biologics, Inc. (the “Company”)
Registration Statement on Form S-1, as amended
File No. 333-186579
Ladies and Gentlemen:
Pursuant to Rule 461 of Regulation C promulgated under the Securities Act of 1933, as amended, the Company hereby requests that the effectiveness of the above-captioned Registration Statement be accelerated to 4:00 p.m. Eastern Time on April 30, 2013, or as soon thereafter as is practicable.
In connection with this letter, the Company acknowledges that:
· should the Securities and Exchange Commission (the “Commission”) or the staff, acting pursuant to delegated authority, declare the filing effective, it does not foreclose the Commission from taking any action with respect to the filing;
· the action of the Commission or the staff, acting pursuant to delegated authority, in declaring the filing effective, does not relieve the Company from its full responsibility for the adequacy and accuracy of the disclosure in the filing; and
· the Company may not assert staff comments and the declaration of effectiveness as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States.
Very truly yours,
ADMA BIOLOGICS, INC.
/s/ Brian Lenz
Brian Lenz
Vice President and Chief Financial Officer